Περίληψη:
Early diagnosis of neurodegenerative disorders such as Alzheimers (AD) or Parkinsons disease (PD) is needed to slow down or halt the disease at the earliest stage. Cerebrospinal fluid (CSF) biomarkers can be a good tool for early diagnosis. However, their use in clinical practice is challenging due to the high variability found between centers in the concentrations of both AD CSF biomarkers (A42, total tau and phosphorylated tau) and PD CSF biomarker (α-synuclein). Such a variability has been partially attributed to different preanalytical procedures between laboratories, thus highlighting the need to establish standardized operating procedures. Here, we merge two previous consensus guidelines for preanalytical confounding factors in order to achieve one exhaustive guideline updated with new evidence for A42, total tau and phosphorylated tau, and α-synuclein. The proposed standardized operating procedures are applicable not only to novel CSF biomarkers in AD and PD, but also to biomarkers for other neurodegenerative disorders. © 2012 Future Medicine Ltd.
Συγγραφείς:
Del Campo, M.
Mollenhauer, B.
Bertolotto, A.
Engelborghs, S.
Hampel, H.
Simonsen, A.H.
Kapaki, E.
Kruse, N.
Le Bastard, N.
Lehmann, S.
Molinuevo, J.L.
Parnetti, L.
Perret-Liaudet, A.
Sáez-Valero, J.
Saka, E.
Urbani, A.
Vanmechelen, E.
Verbeek, M.
Visser, P.J.
Teunissen, C.
Λέξεις-κλειδιά:
alpha synuclein; amyloid beta protein[1-42]; biological marker; DNA; polypropylene; RNA; tau protein, Alzheimer disease; blood sampling; centrifugation; cerebrospinal fluid analysis; circadian rhythm; clinical protocol; consensus development; contamination; diet restriction; DNA determination; early diagnosis; enzyme linked immunosorbent assay; freeze thawing; freezing temperature; human; incubation temperature; length of storage; lumbar puncture; needle; Parkinson disease; practice guideline; protein cerebrospinal fluid level; protein phosphorylation; protein stability; proteomics; review; RNA analysis; rotation; standardization; storage; temperature; tube, alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Biological Markers; Humans; Parkinson Disease; Peptide Fragments; Phase Transition; Specimen Handling; tau Proteins; Temperature
